Get the Stockscreener App
1.08
2.86%
0.03
Dermata Therapeutics Inc Stock (DRMA) Forecast
The Dermata Therapeutics Inc (DRMA) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $7.7484, representing a +617.45% increase from the current price of $1.08. The highest analyst price target is $7.5229, and the lowest is $7.974.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month DRMA Price Target
Average 7.9859
(+639.43% Upside)
Is Dermata Therapeutics Inc (DRMA) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 42.49 | Neutral |
| STOCH(9,6) | 12.33 | Buy |
| STOCHRSI(14) | 13.64 | Buy |
| MACD(12,26) | -0.0541 | Sell |
| ADX(14) | 22.95 | Neutral |
| William %R | -82.22 | Buy |
| CCI(14) | -55.35 | Neutral |
Buy: 3
Sell: 1
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.15
Sell
|
1.1217
Sell
|
| MA20 |
1.1763
Sell
|
1.1653
Sell
|
| MA50 |
1.2671
Sell
|
1.2966
Sell
|
| MA100 |
1.5544
Sell
|
1.7496
Sell
|
| MA200 |
2.8356
Sell
|
3.5122
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, DRMA could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 11 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on DRMA, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 42.49 indicates that DRMA is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 12.33 indicates that DRMA is oversold. This indicates that DRMA price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 13.64 indicates that DRMA is oversold. This suggests that DRMA price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 22.95 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -55.35 indicates that DRMA is still oversold but not to an extreme extent.
Long-term DRMA price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Dermata Therapeutics Inc financial reports and earnings history, Dermata Therapeutics Inc (DRMA) stock could reach $48.03 by 2030, $19.11 by 2040 and $90.16 by 2050. See the projected annual prices until 2050 of the Dermata Therapeutics Inc stock below:
- Dermata Therapeutics Inc (DRMA) is expected to reach an average price of $83.34 in 2035, with a high prediction of $95.62 and a low estimate of $87.09. This indicates an $7,617% rise from the last recorded price of $1.08.
- Dermata Therapeutics Inc (DRMA) stock is projected to chart a bullish course in 2040, with an average price target of $16.10, representing an $1,390% surge from its current level. The forecast ranges from a conservative $16.14 to a sky-high $19.11.
- Our analysts predict Dermata Therapeutics Inc (DRMA) to jump 4,055% by 2045, soaring from $45.11 to an average price of $44.87, potentially reaching $49.03. While $45.11 is the low estimate, the potential upside is significant.
- Dermata Therapeutics Inc (DRMA) stock is expected to climb by 2050, reaching an average of $85.29, a $7,797% jump from its current level. However, a wide range of estimates exists, with high and low targets of $90.16 and $85.30, respectively, highlighting the market's uncertainty.
Dermata Therapeutics Inc Stock (DRMA) Year by Year Forecast
Dermata Therapeutics Inc Stock (DRMA) Price Forecast for 2025
Dermata Therapeutics Inc Stock (DRMA) is expected to reach an average price of $7.9859 in 2025, with a high prediction of $10.49 and a low estimate of $5.4832. This indicates an +639.43% rise from the last recorded price of $1.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $8.7482 | $7.974 | $7.5229 | +710.02% |
| February, 2025 | $8.5336 | $7.5712 | $7.2962 | +690.14% |
| March, 2025 | $6.0469 | $6.3189 | $7.8031 | +459.90% |
| April, 2025 | $4.3306 | $5.5716 | $4.9426 | +300.98% |
| May, 2025 | $11.92 | $5.4832 | $10.31 | +1,004% |
| June, 2025 | $9.4997 | $10.06 | $10.49 | +779.60% |
| July, 2025 | $8.5065 | $8.9129 | $9.0771 | +687.64% |
| August, 2025 | $8.4983 | $8.5887 | $8.1783 | +686.88% |
| September, 2025 | $10.42 | $8.6444 | $8.5336 | +865.15% |
| October, 2025 | $9.4553 | $9.4753 | $10.27 | +775.49% |
| November, 2025 | $8.7806 | $8.3243 | $8.8517 | +713.02% |
| December, 2025 | $7.6623 | $7.7636 | $8.547 | +609.47% |
Dermata Therapeutics Inc Stock (DRMA) Price Forecast for 2026
The predicted value for Dermata Therapeutics Inc (DRMA) in 2026 is set at an average of $3.8358. Estimates vary from a peak of $7.495 to a trough of $0.1767, indicating an +255.17% surge from the present price of $1.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $7.3476 | $7.3476 | $7.495 | +580.34% |
| February, 2026 | $7.013 | $7.013 | $7.1003 | +549.35% |
| March, 2026 | $6.1883 | $6.3083 | $6.6693 | +472.99% |
| April, 2026 | $5.6285 | $5.63 | $5.9746 | +421.16% |
| May, 2026 | $5.2982 | $5.3053 | $5.4065 | +390.58% |
| June, 2026 | $4.538 | $4.5455 | $4.8837 | +320.18% |
| July, 2026 | $3.7015 | $3.7323 | $4.257 | +242.74% |
| August, 2026 | $3.2267 | $3.2576 | $3.5287 | +198.77% |
| September, 2026 | $2.2994 | $2.3394 | $2.892 | +112.90% |
| October, 2026 | $1.6458 | $1.6607 | $2.1156 | +52.39% |
| November, 2026 | $0.955 | $0.9792 | $1.455 | -11.58% |
| December, 2026 | $0.4646 | $0.1767 | $0.7525 | -56.98% |
Dermata Therapeutics Inc Stock (DRMA) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Dermata Therapeutics Inc (DRMA) is $22.74, with a high forecast of $30.22 and a low forecast of $15.25. This indicates an +2,005% increase from the last price of $1.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $11.89 | $15.25 | $22.22 | +1,001% |
| February, 2027 | $26.66 | $17.95 | $25.86 | +2,369% |
| March, 2027 | $23.65 | $27.11 | $27.22 | +2,090% |
| April, 2027 | $25.06 | $24.84 | $23.71 | +2,220% |
| May, 2027 | $28.80 | $24.79 | $26.52 | +2,567% |
| June, 2027 | $30.81 | $28.79 | $28.15 | +2,753% |
| July, 2027 | $30.65 | $30.78 | $30.22 | +2,738% |
| August, 2027 | $28.17 | $26.97 | $25.63 | +2,509% |
| September, 2027 | $26.62 | $26.16 | $26.09 | +2,364% |
| October, 2027 | $25.71 | $24.92 | $24.99 | +2,280% |
| November, 2027 | $22.53 | $22.80 | $24.80 | +1,986% |
| December, 2027 | $19.94 | $21.62 | $21.06 | +1,746% |
Dermata Therapeutics Inc Stock (DRMA) Price Forecast for 2028
In 2028, Dermata Therapeutics Inc (DRMA) is projected to reach an average price of $18.72, with a high projection of $25.22 and a low estimate of $12.21. This indicates an +1,633% rise from the last price of $1.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $26.84 | $20.57 | $25.22 | +2,385% |
| February, 2028 | $23.72 | $24.28 | $25.06 | +2,096% |
| March, 2028 | $21.86 | $22.27 | $22.95 | +1,924% |
| April, 2028 | $21.16 | $21.42 | $21.09 | +1,859% |
| May, 2028 | $22.29 | $21.09 | $22.06 | +1,964% |
| June, 2028 | $20.55 | $20.57 | $21.81 | +1,803% |
| July, 2028 | $19.18 | $18.90 | $19.77 | +1,676% |
| August, 2028 | $17.19 | $17.30 | $18.77 | +1,492% |
| September, 2028 | $16.19 | $16.19 | $16.78 | +1,399% |
| October, 2028 | $15.16 | $15.16 | $15.75 | +1,303% |
| November, 2028 | $13.45 | $13.46 | $14.64 | +1,145% |
| December, 2028 | $12.21 | $12.21 | $13.03 | +1,030% |
Dermata Therapeutics Inc Stock (DRMA) Price Forecast for 2029
The 2029 price forecast for Dermata Therapeutics Inc Stock (DRMA) is $25.32 on average, with a high prediction of $49.95 and a low estimate of $0.6784. This represents an +2,244% increase from the previous price of $1.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $10.60 | $10.84 | $11.81 | +881.79% |
| February, 2029 | $9.2886 | $9.454 | $10.12 | +760.06% |
| March, 2029 | $8.0239 | $8.0547 | $8.9367 | +642.95% |
| April, 2029 | $6.8544 | $6.8853 | $7.6774 | +534.66% |
| May, 2029 | $5.0587 | $5.0987 | $6.346 | +368.40% |
| June, 2029 | $3.7105 | $3.7254 | $4.7013 | +243.56% |
| July, 2029 | $2.325 | $2.3493 | $3.3461 | +115.28% |
| August, 2029 | $1.3136 | $0.6784 | $1.9488 | +21.63% |
| September, 2029 | $35.84 | $39.20 | $46.68 | +3,218% |
| October, 2029 | $49.55 | $41.72 | $49.12 | +4,488% |
| November, 2029 | $46.03 | $51.43 | $49.95 | +4,162% |
| December, 2029 | $46.75 | $46.88 | $45.63 | +4,228% |
Dermata Therapeutics Inc Stock (DRMA) Price Forecast for 2030
Dermata Therapeutics Inc Stock (DRMA) is expected to reach an average price of $42.12 in 2030, with a high forecast of $50.11 and a low forecast of $34.13. This signifies an +3,800% surge from the last price of $1.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $51.26 | $46.31 | $48.03 | +4,646% |
| February, 2030 | $50.94 | $49.26 | $48.77 | +4,616% |
| March, 2030 | $50.09 | $50.21 | $50.11 | +4,538% |
| April, 2030 | $46.91 | $46.05 | $44.37 | +4,244% |
| May, 2030 | $44.48 | $44.21 | $44.65 | +4,019% |
| June, 2030 | $42.88 | $42.27 | $42.69 | +3,870% |
| July, 2030 | $37.84 | $38.68 | $41.80 | +3,403% |
| August, 2030 | $35.55 | $37.23 | $37.20 | +3,192% |
| September, 2030 | $41.75 | $35.66 | $40.14 | +3,766% |
| October, 2030 | $37.78 | $38.50 | $39.63 | +3,398% |
| November, 2030 | $35.21 | $35.62 | $36.82 | +3,160% |
| December, 2030 | $33.81 | $34.13 | $34.27 | +3,031% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):